At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Mar 23, 2026 at 07:30 ET
Palvella Therapeutics announced the appointment of Jennifer McDonough as Senior Vice President of Market Access and Patient Services, leveraging her experience from Krystal Biotech's successful VYJUVEK® launch to prepare for a potential U.S. commercialization of QTORIN™ rapamycin for microcystic lymphatic malformations. The move signals advancing commercial readiness ahead of a potential FDA approval, though no new clinical or regulatory milestones were announced.
- Jennifer McDonough appointed as SVP of Market Access and Patient Services at Palvella Therapeutics.
- McDonough previously led patient access and operations at Krystal Biotech, contributing to VYJUVEK®'s growth to $389M in annual sales by 2025 after its 2023 FDA approval.
- Palvella is preparing for a potential near-term U.S. launch of QTORIN™ rapamycin for microcystic lymphatic malformations, following positive Phase 3 SELVA results.
- No new clinical data, regulatory decisions, or financial figures were disclosed in the press release.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access